Learn how LucyRx and Abarca Health are combining to create a modern independent PBM, delivering scalable pharmacy benefits, specialty care expertise, and advanced healthcare technology.
MedCity News examines the planned combination of LucyRx and Abarca Health, highlighting how the two independent PBMs aim to expand scale, strengthen transparency, and serve commercial and government clients amid growing scrutiny of the pharmacy benefit management industry.
Managed Healthcare Executive examines the LucyRx and Abarca Health combination and its focus on scale, technology, and innovation in the PBM market.
David Blair, Founder and CEO of LucyRx, has been named an EY US Entrepreneur Of The Year® 2026 Mid-Atlantic Award winner, recognizing his leadership, innovation, and impact in transforming prescription care.
Managed Healthcare Executive reported on the strategic combination of LucyRx and Abarca Health, two independent PBMs joining forces to serve more than 9 million members across the United States.
Forbes Highlights LucyRx and Abarca Health Strategic Combination as an Alternative to the Big Three PBMs.
The Abarca Health and LucyRx combination creates a larger independent PBM alternative while preserving continuity for clients and members. Becker’s Payer examines what the transaction reflects about employer demand for greater transparency, flexibility, and accountability in prescription care.
Abarca Health and LucyRx unite to form the only modern, independent PBM serving commercial and government clients at scale—9M+ members nationwide.
Forbes highlights the planned LucyRx and Abarca Health combination as part of a broader PBM market shift toward greater scale, innovation and accountability.
CAA 2026 could reshape PBM oversight, incentives, and the prescription care experience. In this Drug Topics discussion, LucyRx CEO David Blair considers why meaningful reform must translate into transparency, fair access, and accountability for employers, pharmacies, and members.